Benefits
Stimulant/sympathomimetic effects (animal evidence)
Hapke 1995 (PMID 8542915, Dtsch Tierarztl Wochenschr) demonstrated in dogs and rats that hordenine produced positive inotropic effect on heart, increased systolic and diastolic BP, and increased peripheral blood flow. Effects via indirect adrenergic activity (norepinephrine release). CRITICAL CAVEAT: effects were short-lived and required HIGH DOSES — performance enhancement in racehorses unlikely. Human translation has not been rigorously demonstrated.
Weak MAO-B inhibitor (potentiates other PEAs)
Hordenine is a selective substrate for MAO-B with weak inhibitory activity (Km = 479 μM, Vmax = 128 nM/mg protein/h in rat liver). Theoretical mechanism for potentiating phenylethylamine (PEA) and other monoamines that are MAO-B substrates. Combined with PEA in some pre-workouts to extend duration. NOT a clinically meaningful MAOI like prescription drugs (selegiline, etc.) — far weaker effect.
NO direct lipolytic activity (Haj Ahmed 2021)
Haj Ahmed 2021 study directly tested hordenine effects on adipocyte lipolysis. RESULT: hordenine does NOT activate or inhibit lipolysis in fat cells. Adipocytes were responsive to standard stimulants (isoprenaline, forskolin) and inhibitors (insulin) but unresponsive to hordenine. Authors concluded: 'Hordenine consumption cannot likely increase lipid mobilization from fat depots since this plant alkaloid is lacking noticeable lipolytic effect.' Direct evidence against fat-burner marketing claims.
Indirect adrenergic activity (norepinephrine release)
Hordenine acts as indirect adrenergic agonist by promoting norepinephrine release from sympathetic nerve terminals. Mechanism similar to (but weaker than) tyramine and amphetamines. Theoretical contribution to focus and energy through SNS activation — but actual clinical effects in humans are minimal at safe doses.
Bronchodilation (traditional Chinese use)
Used in Traditional Chinese Medicine as 'mao gen' for respiratory conditions including asthma — bronchodilator activity via β-adrenergic indirect effects. Mechanism plausible but rigorous clinical evidence in respiratory conditions absent. Modern bronchodilators (β2-agonists) far more effective.
Mechanism of action
Indirect adrenergic activity via norepinephrine release
Hordenine, like tyramine and amphetamines, is an indirect-acting sympathomimetic — it promotes release of stored norepinephrine from sympathetic nerve terminals. Mechanism does NOT involve direct receptor binding (unlike epinephrine). Effects depend on existing sympathetic tone and norepinephrine stores. Tachyphylaxis can develop with repeated use.
Selective MAO-B inhibition (weak)
Selectively inhibits MAO-B isoenzyme over MAO-A. In context of PEA potentiation: PEA is rapidly metabolized by MAO-B; hordenine slows this metabolism. However, hordenine itself is also an MAO-B substrate at low concentrations — making it a 'mixed substrate/inhibitor.' Inhibitory activity is weak relative to selective MAOI drugs.
Crosses blood-brain barrier
Lipophilic structure allows penetration into CNS. Theoretically supports nootropic/focus claims, but actual brain levels achieved at oral supplement doses are likely low. CNS effects in humans have not been rigorously characterized via PET imaging or microdialysis studies.
NO direct β-adrenergic agonism in adipocytes
Despite weight loss marketing, hordenine does NOT bind β-adrenergic receptors directly in adipocytes (Haj Ahmed 2021). Cannot stimulate lipolysis directly. Any weight management effects would have to come from indirect mechanisms (SNS activation generally) — which are modest at safe doses.
Clinical trials
Veterinary pharmacology study (Frank M, Weckman TJ, Wood T, Woods WE, Tai CL, Chang SL, Ewing A, Blake JW, Tobin T 1990, Equine Vet J 22(6):437-441, doi:10.1111/j.2042-3306.1990.tb04313.x).
Horses given oral and intravenous hordenine. Pharmacokinetics (plasma concentration), behavioral effects, vital signs, and respiratory effects measured.
Intravenous administration caused immediate behavioral changes and significant respiratory distress, but symptoms subsided within 30 minutes. Oral administration showed NO noticeable changes — consistent with poor oral bioavailability. Pharmacokinetic analysis revealed rapid plasma clearance, with no lasting stimulant or depressive effects post-dosing. Foundational evidence that oral hordenine produces minimal systemic effects.
Animal pharmacology study (Hapke HJ, Strathmann W 1995, Dtsch Tierarztl Wochenschr 102(6):228-232, PMID 8542915).
Dogs and rats given hordenine orally and intravenously. Cardiovascular, gastrointestinal, and CNS effects assessed; isolated tissue experiments to elucidate mechanism.
Hordenine produced positive inotropic effect, increased BP, increased peripheral blood flow, inhibited GI movements. Effects characterized as INDIRECTLY ACTING ADRENERGIC mechanism via norepinephrine release. CRITICAL CAVEAT: effects were short-lived and required HIGH DOSES to be observed. Animal findings do not translate directly to human supplement doses.
Adipocyte study (Haj Ahmed W et al. 2021, Integr Food Nutr Metab 8:302).
Mouse fat cells (adipocytes) and human subcutaneous adipose tissue homogenates exposed to hordenine and assessed for lipolytic and antilipolytic responses, plus interaction with monoamine oxidase.
DIRECT EVIDENCE that hordenine does NOT activate or inhibit lipolysis in adipocytes. Cells were responsive to standard agents (isoprenaline, forskolin, insulin) but unresponsive to hordenine. Confirmed weak MAO interaction (substrate/inhibitor) but no direct fat-cell stimulation. Authors concluded: 'Hordenine consumption cannot likely increase lipid mobilization from fat depots.' Foundational counter-evidence against fat burner marketing claims.
About this ingredient
Hordenine (N,N-dimethyltyramine, β-(p-hydroxyphenyl)ethyl-dimethylamine, p-hydroxy-β-phenylethyldimethylamine) is a phenethylamine alkaloid — chemically related to tyramine, dopamine, and other biogenic amines. Discovered in barley sprouts (Hordeum vulgare) — hence the name. Also found in: BITTER ORANGE (Citrus aurantium) — major commercial supplement source; CACTI including Lophophora williamsii (peyote) and Anhalonium fissuratum; Senecio scandens; Pancratium maritimum; Polyalthia longifolia; some red algae (Gigartina stellata).
PHARMACOLOGY characterized primarily in 1990s-2000s animal studies. Acts as INDIRECT ADRENERGIC AGONIST via norepinephrine release (similar mechanism to tyramine and amphetamines but weaker). Selective MAO-B inhibitor with weak Km/Vmax values.
Rapid plasma clearance after dosing; oral bioavailability is moderate but produces only short-lived effects requiring high doses for observable pharmacology. Marketed in supplements primarily as: STIMULANT/PRE-WORKOUT (boost energy, focus), FAT BURNER (despite NO direct lipolytic activity per Haj Ahmed 2021), PEA POTENTIATOR (extending duration of phenylethylamine effects via MAO-B inhibition). Combined with caffeine, synephrine, yohimbine, phenylethylamine in many pre-workout and weight management products.
FDA classified hordenine as a New Dietary Ingredient (NDI) requiring proper notification — many products technically adulterated without filings. EVIDENCE: 1/5 reflects: (1) Frank 1990 PMID 2148167 horse PK study showing minimal effects after oral dosing, (2) Hapke 1995 PMID 8542915 dog/rat pharmacology with short-lived effects, (3) Haj Ahmed 2021 adipocyte study DIRECTLY DISPROVING lipolytic activity, (4) absence of human RCTs investigating supplement claims, (5) traditional Chinese medicinal use as 'mao gen' for respiratory conditions. The marketing-evidence gap is substantial.
SAFETY: Generally well-tolerated at typical supplement doses but theoretical cardiovascular concerns; significant practical concerns include drug screen false positives and FDA regulatory status. Best positioned as: (a) NOT a recommended fat burner — direct adipocyte evidence shows no effect, (b) modest pre-workout stimulant adjunct (most users report subtle effects), (c) PEA potentiator in stacks (where the synergy may add value), (d) NOT a substitute for evidence-based stimulants like caffeine, (e) AVOID in cardiovascular conditions, drug-tested individuals (false positives), and pregnancy. Honest framing: hordenine is a textbook example of pre-workout/fat-burner marketing exceeding evidence.
The pharmacology in animals shows real but modest indirect adrenergic activity; the direct disproof of lipolytic activity in 2021 is important context that consumers rarely encounter.